BMY Q3 2021 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q3 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.6B+10.3% YoY

Gross Profit

$6.8B58.2% margin

Operating Income

$1.7B14.9% margin

Net Income

$1.5B13.3% margin

EPS (Diluted)

$0.69

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

$5.3B

Free Cash Flow

$5.0B

Stock-Based Comp.

$142M

Balance Sheet

Total Assets

$110.9B

Total Liabilities

$73.6B

Stockholders' Equity

$37.2B

Cash & Equivalents

$13.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.6B	$10.5B	+10.3%
Gross Profit	$6.8B	$5.6B	+21.7%
Operating Income	$1.7B	$1.4B	+26.8%
Net Income	$1.5B	$1.9B	-17.4%

Revenue Segments

Revlimid

$3.3B29%

Eliquis

$2.4B21%

Opdivo

$1.9B17%

Orencia

$870M8%

Pomalyst/Imnovid

$851M7%

Sprycel

$551M5%

Yervoy

$515M5%

Mature Products And All Other

$339M3%

Abraxane

$266M2%

Reblozyl

$160M1%

Abecma

$71M1%

Zeposia

$40M0%

Breyanzi

$30M0%

Geographic Segments

UNITED STATES

$7.3B63%

Europe

$2.7B23%

Rest Of World

$1.4B12%

Other Region

$276M2%